TZTing-Ting Zhao

Ting-Ting Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ting-Ting Zhao has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Bo Guo

    Department of Cell Biology and Genetics, School of Basic Medical Sciences, Xi’an Jiaotong University Health Science Center

    1 shared publication
  • Fei Han

    Department of Obstetrics and Gynecology, Women and Children's Hospital of Chongqing Medical University, Chongqing 401147, China; Department of Health Toxicology, School of Public Health, Chongqing Medical University, Chongqing 400016, China

    1 shared publication
  • Fei Yang

    Department of Neurology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China

    1 shared publication
  • Gui-Lian Xu

    Department of Immunology, Army Medical University, Chongqing, China

    1 shared publication
  • Ke-Qin Zhang

    National Engineering Laboratory for Modern Silk, College of Textile and Clothing Engineering, Soochow University, Suzhou

    1 shared publication
  • Man Jiang

    Department of Physiology, School of Basic Medicine and Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    1 shared publication

Latest Publications

  • Open Access

    SOX30 Facilitates Triple‐Negative Breast Cancer Metastasis via TNFR2–NF‐κB Signaling and Tumor Microenvironment Remodeling

    by Pingping Gao, Na Sun, Ning Yang, Tingting Zhao, Rui Fu, Zhenyu Wu, Yuqin Zhou, Xuanni Tan, Yi Zhang, Fei Han, et al.

    Triple‐negative breast cancer (TNBC) remains therapeutically challenging due to its aggressive metastatic potential, high recurrence rates, and lack of effective targeted therapies. Herein, we identified that SOX30 is significantly upregulated in TNBC and correlates with poor clinical prognosis. Functionally, SOX30 specifically drives TNBC metastasis and activates the TNFR2‐mediated downstream NF‐κB signaling cascade. Mass cytometry profiling of the tumor immune microenvironment revealed that SOX30 facilitates the recruitment of tumor‐associated macrophages (TAMs) within pulmonary metastases, a finding corroborated by flow cytometric quantification. Mechanistically, downstream pathway analyses identified that SOX30 induces activation of the TNFR2–NF‐κB axis and concurrently upregulates expression of the chemokine CCL20. Therapeutic intervention with CCL20 neutralizing antibodies or small‐molecule CCR6 inhibitors effectively attenuated metastatic progression and abrogated TAM infiltration. Strikingly, combinatorial blockade using the TNFR2 inhibitor etanercept together with a CCR6 inhibitor exhibited superior anti‐metastatic efficacy relative to control treatments. Collectively, our findings delineate a novel oncogenic SOX30–TNFR2–NF‐κB–CCL20/CCR6 axis driving TNBC metastasis. These results establish SOX30 as a promising prognostic biomarker and a potential therapeutic target for anti‐metastatic strategies in TNBC.

  • Induction of protective and therapeutic antitumor immunity by a DNA vaccine with C3d as a molecular adjuvant

    by Gui-Lian Xu, Ke-Qin Zhang, Bo Guo, Ting-Ting Zhao, Fei Yang, Man Jiang, Qing-Hong Wang, Yu-Hang Shang, Yu-Zhang Wu